Patents Represented by Attorney Robert C. Hall

Find this attorney in the Justia Lawyer Directory

  • Antibodies against human IL17 and uses thereof
    Patent number: 8003099
    Abstract: An antibody binding to IL-17 characterized by binding to the same IL-17 epitope to which monoclonal antibody 3C1 binds, and being of human IgG1 isotype modified in the hinge region at amino acid position 216-240, preferably at amino acid position 220-240, between CH1 and CH2 and/or in the second inter-domain region at amino acid position 327-331 between CH2 and CH3 has advantageous properties for the treatment of inflammatory diseases.
    Type: Grant
    Filed: September 29, 2009
    Date of Patent: August 23, 2011
    Assignee: Roche Palo Alto LLC
    Inventors: Johannes Auer, Nikolaos Dimoudis, Guy Georges, Petra Hanke, Hendrik Knoetgen, Ekkehard Moessner, Claire Louise Langrish
  • Arylpiperazine derivatives and uses thereof
    Patent number: 7998963
    Abstract: Compounds of formula I: or pharmaceutically acceptable salts thereof, wherein Ar is indolyl, indazolyl or dihydroindolyl, and R1, R2, R3 and R4 are as defined herein. Also provided are pharmaceutical compositions, methods of using the compounds in the treatment of depressive, anxiolytic and other disorders associated with inhibition of the reuptake of norepinephrine, serotonin, and dopamine, and methods of preparing the compounds.
    Type: Grant
    Filed: February 12, 2009
    Date of Patent: August 16, 2011
    Assignee: Roche Palo Alto LLC
    Inventors: David Scott Carter, Matthew C. Lucas, Ryan Craig Schoenfeld, Robert James Weikert
  • Triazole-substituted arylamides as P2Xand P2Xantagonists
    Patent number: 7989637
    Abstract: Compounds of the formula I: or a pharmaceutically acceptable salt thereof, wherein, R1 is optionally substituted triazolyl, and R2, R3, R4, R5, R6, R7 and R8 are as defined herein. Also disclosed are methods of using the compounds for treating diseases associated with P2X3 and/or a P2X2/3 receptor antagonists and methods of making the compounds.
    Type: Grant
    Filed: December 17, 2008
    Date of Patent: August 2, 2011
    Assignee: Roche Palo Alto LLC
    Inventors: Li Chen, Michael Patrick Dillon, Lichun Feng, Ronald Charles Hawley, Minmin Yang
  • Tetralin and indane derivatives and uses thereof
    Patent number: 7981923
    Abstract: Compounds of the formula I, II or III: or pharmaceutically acceptable salts thereof, wherein m, n, q, Ar, R1, R2, R3, R4 and R5 are as defined herein. Also provided are methods for preparing, compositions comprising, and methods for using compounds of formulas I-III.
    Type: Grant
    Filed: January 26, 2010
    Date of Patent: July 19, 2011
    Assignee: Roche Palo Alto LLC
    Inventors: Ralph New Harris, III, James M. Kress, David Bruce Repke, Russell Stephen Stabler
  • Tetrazole-substituted aryl amide derivatives and uses thereof
    Patent number: 7981914
    Abstract: Compounds of the formula: wherein R1, R2, Ar1, Ar2, and n are as defined herein. Also provided are pharmaceutical compositions, methods of using, and methods of preparing the subject compounds.
    Type: Grant
    Filed: October 1, 2008
    Date of Patent: July 19, 2011
    Assignee: Roche Palo Alto LLC
    Inventors: Daisy Joe Du Bois, Todd Richard Elworthy, Hans Maag, Sunil Sahdeo
  • Conjugate of an antibody against CCR5 and an antifusogenic peptide
    Patent number: 7951920
    Abstract: The current invention is related to a conjugate comprising one or more antifusogenic peptides and an anti-CCR5 antibody (mAb CCR5) characterized in that one to eight antifusogenic peptides are each conjugated to one terminus of the heavy and/or light chains of the anti-CCR5 antibody and to the pharmaceutical use of the conjugate.
    Type: Grant
    Filed: August 17, 2007
    Date of Patent: May 31, 2011
    Assignee: Roche Palo Alto LLC
    Inventors: Michael Brandt, Stephan Fischer, Erhard Kopetzki, Suryanarayana Sankuratri, Ralf Schumacher
  • Assays for measuring phosphate modification enzyme activity
    Patent number: 7901901
    Abstract: The present invention relates to assays that can measure the activity of enzymes that catalyze phosphate modifications, such as kinases, phosphatases, cyclases and phosphodiesterases. The assays can also be used to identify and screen for substances that modulate the activity of kinases, phosphatases, cyclases and phosphodiesterases.
    Type: Grant
    Filed: December 9, 2009
    Date of Patent: March 8, 2011
    Assignee: Roche Palo Alto LLC
    Inventor: Qing-Fen Gan
  • Anti-OX40L antibodies
    Patent number: 7868141
    Abstract: This invention relates to anti-OX40L antibodies and, in particular, to anti-OX40L antibodies and variants thereof that contain a Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suffering from inflammatory diseases.
    Type: Grant
    Filed: December 5, 2008
    Date of Patent: January 11, 2011
    Assignee: Roche Palo Alto LLC
    Inventors: Joseph Endl, Elsie M. Eugui, Maria Elena Fuentes, Yvo Graus, Aran Frank Labrijn, Martin Lanzendoerfer, Paul Parren, Frank Rebers, Ralf Schumacher, Stefan Seeber, Jan Van De Winkel, Martine Van Vugt
  • 3-amino-1-arylpropyl indoles as monoamine reuptake inhibitors
    Patent number: 7863305
    Abstract: Compounds of formula I: or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein p, Ar, R1, R2, R3, Ra, Rb, Rc, Rd and Re are defined herein. Also provided are pharmaceutical compositions, methods of using, and methods of preparing the compounds.
    Type: Grant
    Filed: June 1, 2005
    Date of Patent: January 4, 2011
    Assignee: Roche Palo Alto LLC
    Inventors: Robert Greenhouse, Saul Jaime-Figueroa, Lubica Raptova, Deborah Carol Reuter, Karin Ann Stein, Robert Weikert
  • Diaminopyrimidines as P2Xand P2Xantagonists
    Patent number: 7858632
    Abstract: Compounds and methods for treating diseases mediated by a P2X3 and/or a P2X2/3 receptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of formula (I): or a pharmaceutically acceptable salt, solvate or prodrug thereof, wherein D, X, Y, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein.
    Type: Grant
    Filed: March 3, 2005
    Date of Patent: December 28, 2010
    Assignee: Roche Palo Alto LLC
    Inventors: Chris Allen Broka, David Scott Carter, Michael Patrick Dillon, Ronald Charles Hawley, Alam Jahangir, Clara Jeou Jen Lin, Daniel Warren Parish
  • Imidazole-substituted arylamides as P2Xand P2Xantagonists
    Patent number: 7858654
    Abstract: Compounds of the formula I: wherein R1 is optionally substituted imidazolyl, and R2, R3, R4, R5, R6, R7 and R8 are as defined herein. Also provided are methods of using the compounds for treating diseases mediated by a P2X3 and/or a P2X2/3 receptor antagonist and methods of making the subject compounds.
    Type: Grant
    Filed: December 17, 2008
    Date of Patent: December 28, 2010
    Assignee: Roche Palo Alto LLC
    Inventors: Li Chen, Michael Patrick Dillon, Lichun Feng, Ronald Charles Hawley, Minmin Yang
  • 3-amino-1-arylpropyl indoles and AZA-substituted indoles and uses thereof
    Patent number: 7803830
    Abstract: The present invention provides compounds of the formula: or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein p, Ar, R1, R2, R3, Ra, Rb, Rc, Rd and Re are defined herein. Also provided are pharmaceutical compositions, methods of using, and methods of preparing the compounds.
    Type: Grant
    Filed: October 8, 2008
    Date of Patent: September 28, 2010
    Assignee: Roche Palo Alto LLC
    Inventors: Pravin Iyer, Matthew C. Lucas, Ryan Craig Schoenfeld, Marzia Villa, Robert James Weikert
  • Imidazolinylmethyl aryl sulfonamide
    Patent number: 7799816
    Abstract: This invention relates to an alpha-1 A receptor partial agonist, which is represented by Formula I: and pharmaceutically acceptable salts or solvates thereof. The invention further relates to pharmaceutical compositions containing formula I, methods for their use as therapeutic agents, and methods of preparation thereof.
    Type: Grant
    Filed: February 4, 2009
    Date of Patent: September 21, 2010
    Assignee: Roche Palo Alto LLC
    Inventors: Counde O'Yang, Robert Greenhouse
  • Arylsulfonyl naphthalene derivatives and uses thereof
    Patent number: 7799797
    Abstract: Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein m, q, Ar, R1, R2 and R7 are as defined herein. Also provided are methods for preparing, compositions comprising, and methods for using compounds of formula I.
    Type: Grant
    Filed: June 20, 2007
    Date of Patent: September 21, 2010
    Assignee: Roche Palo Alto LLC
    Inventor: Ralph New Harris, III
  • Diaminopyrimidines as P2Xand P2Xmodulators
    Patent number: 7799796
    Abstract: Compounds and methods for treating diseases mediated by a P2X3 and/or a P2X2/3 receptor antagonist, the compounds being of formula (I): wherein D, X, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein.
    Type: Grant
    Filed: August 25, 2006
    Date of Patent: September 21, 2010
    Assignee: Roche Palo Alto LLC
    Inventors: Michael Patrick Dillon, Alam Jahangir, Clara Jeou Jen Lin
  • Thiazole and oxazole-substituted arylamides as P2Xand P2Xantagonists
    Patent number: 7786110
    Abstract: Compounds of the formula I: or a pharmaceutically acceptable salt thereof, wherein, R1 is a group of formula A or formula B, and X, R2, R3, R4, R5, R6, Ra and Rb are as defined herein. Also provided are methods of using the compounds for treating diseases mediated by a P2X3 and/or a P2X2/3 receptor antagonist and methods of making the subject compounds.
    Type: Grant
    Filed: November 8, 2007
    Date of Patent: August 31, 2010
    Assignee: Roche Palo Alto LLC
    Inventors: Michael Patrick Dillon, Ronald Charles Hawley, Li Chen, Lichun Feng, Minmin Yang
  • Diaminopyrimidines as P2Xand P2Xmodulators
    Patent number: 7776872
    Abstract: Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein A, D, E, G, J, X, Y, Z R6, R7 and R8 are as defined herein. Also provided are methods of using the compounds for treating diseases mediated by a P2X3 and/or a P2X2/3 receptor antagonist and methods of making the compounds.
    Type: Grant
    Filed: August 25, 2006
    Date of Patent: August 17, 2010
    Assignee: Roche Palo Alto LLC
    Inventors: Michael Patrick Dillon, Alam Jahangir, Alfred Sui-Ting Lui, Robert Stephen Wilhelm
  • Chroman derivatives and uses thereof
    Patent number: 7759389
    Abstract: Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein m, p, q, Ar, R1, R2, R3 and R4 are as defined herein. Also provided are methods for preparing, compositions comprising, and methods for using compounds of formula I.
    Type: Grant
    Filed: December 21, 2005
    Date of Patent: July 20, 2010
    Assignee: Roche Palo Alto LLC
    Inventors: Nancy Elisabeth Krauss, Shu-Hai Zhao
  • Arylpiperazine derivatives and uses thereof
    Patent number: 7754721
    Abstract: Compounds of the formula: or pharmaceutically acceptable salts thereof, wherein m, n, X, Y, Z, Ar, R1, R2, R3, R4, R5, R6 and R7 are defined herein. Also provided are pharmaceutical compositions, methods of using, and methods of preparing the compounds.
    Type: Grant
    Filed: August 17, 2007
    Date of Patent: July 13, 2010
    Assignee: Roche Palo Alto LLC
    Inventors: David Scott Carter, Ryan Craig Schoenfeld, Robert James Weikert
  • Arylsulfonyl chromans as 5-HTinhibitors
    Patent number: 7754759
    Abstract: Compounds of the formula I: wherein m, n, p, X, Ar, R1, R2, R3, R4 and R5 are as defined herein. Methods of making the compounds and using the compounds for treatment of 5-HT6 receptor-mediated diseases are disclosed.
    Type: Grant
    Filed: November 3, 2006
    Date of Patent: July 13, 2010
    Assignee: Roche Palo Alto LLC
    Inventors: Jacob Berger, Joan Marie Caroon, Francisco Javier Lopez-Tapia, Lee Edwin Lowrie, Jr., Dov Nitzan, Shu-Hai Zhao